AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23579543 — intervention group
Group type: COMPARATOR
Intervention: Patients without DGE
Number of subjects: 101
Study 20210904 — intervention group
Group type: EXPERIMENTAL
Intervention: Football group (FG) - trained 2.4 times/week for 12 weeks and 1.3 sessions/week for 52 weeks
Number of subjects: 17
Study 20210904 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no intervention
Number of subjects: 17
Study 19028953 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-taken pharyngeal swabs for GC
Number of subjects: 272
Study 19028953 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-taken rectal swabs for GC
Number of subjects: 272
Study 19028953 — intervention group
Group type: COMPARATOR
Intervention: Nurse-taken pharyngeal swabs for GC
Number of subjects: 272
Study 19028953 — intervention group
Group type: COMPARATOR
Intervention: Nurse-taken rectal swabs for GC
Number of subjects: 272
Study 19028953 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-taken rectal swabs for CT
Number of subjects: 272
Study 19028953 — intervention group
Group type: COMPARATOR
Intervention: Nurse-taken rectal swabs for CT
Number of subjects: 272
Study 16909964 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltitrexed 3 mg/m2 every 3 weeks and mitomycin-C 7 mg/m2 every 6 weeks for up to 24 weeks
Number of subjects: 22
Study 12816777 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried peas (meal 1)
Number of subjects: 0
Study 12816777 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dried peas and potatoes (meal 2)
Number of subjects: 0
Study 12816777 — intervention group
Group type: COMPARATOR
Intervention: Potatoes (meal 3)
Number of subjects: 0
Study 10849894 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of valproic acid (800 mg) administered at 8:00 PM
Number of subjects: 12
Study 10849894 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of valproic acid (800 mg) administered at 5:00 AM
Number of subjects: 12
Study 10423609 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg quinapril once daily
Number of subjects: 131
Study 10423609 — intervention group
Group type: COMPARATOR
Intervention: 12.5 mg captopril twice daily
Number of subjects: 131
Study 1347260 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 mg d-1)
Number of subjects: 0
Study 1347260 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg day-1)
Number of subjects: 0
Study 1347260 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80-480 mg)
Number of subjects: 0
Study 4029018 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin 1g intravenously
Number of subjects: 15
Study 4029018 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocillin 1g intramuscularly
Number of subjects: 15
Study 4029018 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-functioning gallbladders)
Number of subjects: 15
Study 30426896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous and intraperitoneal chemotherapy
Number of subjects: 49
Study 30426896 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy
Number of subjects: 49
Study 27634943 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training intervention (3 times per week, 60 min per session for 16 weeks)
Number of subjects: 37
Study 27634943 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training intervention
Number of subjects: 37
Study 27634943 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention follow-up
Number of subjects: 37
Study 24438771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D) supplementation for 20 weeks
Number of subjects: 30
Study 24438771 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 30
Study 23726933 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic intervention (n=49) including pharmaceutical management, multimodal physiotherapy, and psychology for post-traumatic stress.
Number of subjects: 101
Study 23726933 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 101
Study 19830704 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (specific treatment not mentioned)
Number of subjects: 0
Study 19830704 — intervention group
Group type: COMPARATOR
Intervention: Treatment B (specific treatment not mentioned)
Number of subjects: 0
Study 17961561 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 50
Study 17961561 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 50
Study 16013019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 18
Study 16013019 — intervention group
Group type: COMPARATOR
Intervention: THAM
Number of subjects: 18
Study 12973582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic clinical trials
Number of subjects: 0
Study 10536544 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 200 mg
Number of subjects: 20
Study 10536544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8800823 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ordination group (nurse coordinators assisting patients)
Number of subjects: 167
Study 8800823 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ordination group
Number of subjects: 167
Study 8800823 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 167
Study 2070206 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant intravenous cisplatin therapy
Number of subjects: 255
Study 2070206 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 255
Study 6421424 — intervention group
Group type: EXPERIMENTAL
Intervention: Human ultralente insulin
Number of subjects: 18
Study 6421424 — intervention group
Group type: COMPARATOR
Intervention: Beef ultralente insulin
Number of subjects: 18
Study 30130421 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 203
Study 30130421 — intervention group
Group type: COMPARATOR
Intervention: No-CPAP treatment
Number of subjects: 203
Study 29053848 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 143
Study 29053848 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 143
Study 27067467 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Catheter (ACC)
Number of subjects: 96
Study 27067467 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular Catheter (IAC)
Number of subjects: 96
Study 24962451 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing by lay health-care workers (LHCWs)
Number of subjects: 409
Study 24962451 — intervention group
Group type: COMPARATOR
Intervention: Brief smoking cessation advice from a TB nurse (control group)
Number of subjects: 409
Study 22879203 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride treatment
Number of subjects: 1247
Study 22879203 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1247
Study 20236631 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG+CC
Number of subjects: 230
Study 20236631 — intervention group
Group type: COMPARATOR
Intervention: hMG alone
Number of subjects: 230
Study 23350617 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL-1
Number of subjects: 40
Study 23350617 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL-2
Number of subjects: 40
Study 16168485 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp optic edge PMMA intraocular lens
Number of subjects: 32
Study 16168485 — intervention group
Group type: COMPARATOR
Intervention: Round optic edge PMMA intraocular lens
Number of subjects: 32
Study 12507837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIPX) + Metronidazole (MTR)
Number of subjects: 135
Study 12507837 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (CTRX) + Metronidazole (MTR)
Number of subjects: 135
Study 10772195 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and betamethasone (group A)
Number of subjects: 29
Study 10772195 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin alone (group B)
Number of subjects: 29
Study 10772195 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone (group C)
Number of subjects: 29
Study 10772195 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group D)
Number of subjects: 29
Study 8787365 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal recall of tetanus toxoid vaccination
Number of subjects: 1477
Study 2058612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 1.0 micrograms/kg/min for 72 hours
Number of subjects: 49
Study 2058612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion at 2.5 micrograms/kg/min for 72 hours
Number of subjects: 49
Study 2058612 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dopamine)
Number of subjects: 49
Study 2058612 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion (both doses)
Number of subjects: 49
Study 6222636 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 33-824 (0.5 mg)
Number of subjects: 12
Study 6222636 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 33-824 (2 mg)
Number of subjects: 12
Study 6222636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29187304 — intervention group
Group type: EXPERIMENTAL
Intervention: Online supermarket shopping for 3 months
Number of subjects: 0
Study 29187304 — intervention group
Group type: COMPARATOR
Intervention: Usual grocery store shopping for 3 months
Number of subjects: 0
Study 28281112 — intervention group
Group type: EXPERIMENTAL
Intervention: Kymerax© Precision‐Drive Articulating Surgical System
Number of subjects: 45
Study 28281112 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic instruments (TLI)
Number of subjects: 45
Study 26614599 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption (<1 cup/day)
Number of subjects: 90317
Study 26614599 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption (1 cup/day)
Number of subjects: 90317
Study 26614599 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption (2-3 cups/day)
Number of subjects: 90317
Study 26614599 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption (4-5 cups/day)
Number of subjects: 90317
Study 26614599 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption (≥6 cups/day)
Number of subjects: 90317
Study 26614599 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 90317
Study 26614599 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee additives
Number of subjects: 90317
Study 26614599 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 90317
Study 23467551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate in MLE cream
Number of subjects: 175
Study 23467551 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone aceponate cream
Number of subjects: 175
Study 21926653 — intervention group
Group type: EXPERIMENTAL
Intervention: PureVision Low Add
Number of subjects: 10
Study 21926653 — intervention group
Group type: EXPERIMENTAL
Intervention: PureVision High Add
Number of subjects: 10
Study 21926653 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus Progressives
Number of subjects: 10
Study 21926653 — intervention group
Group type: COMPARATOR
Intervention: Single vision lens
Number of subjects: 10
Study 18670308 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotaxel (50 mg/m) + cisplatin (75 mg/m) every 3 weeks (arm A)
Number of subjects: 62
Study 18670308 — intervention group
Group type: COMPARATOR
Intervention: Larotaxel (60 mg/m) + gemcitabine (800 mg/m) every 3 weeks (arm B)
Number of subjects: 62
Study 16756691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright-light therapy combined with sertraline
Number of subjects: 0
Study 16756691 — intervention group
Group type: COMPARATOR
Intervention: Dim-light therapy combined with sertraline
Number of subjects: 0
Study 12834132 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching before and after each physical training session (518 recruits)
Number of subjects: 901
Study 12834132 — intervention group
Group type: COMPARATOR
Intervention: Non-stretching (383 recruits)
Number of subjects: 901
Study 10994859 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 0.142 mg/kg x min
Number of subjects: 12
Study 10994859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 12
Study 8865952 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Methylpyrazole (4-MP) at doses of 10 to 20 mg/kg
Number of subjects: 16
Study 8865952 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.6 g/kg followed by 0.2 g/kg twice)
Number of subjects: 16
Study 1514885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (60 to 264 micrograms per day)
Number of subjects: 3
Study 1514885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen
Number of subjects: 3
Study 6137168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 0
Study 6137168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 0
Study 6137168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 0
Study 30518334 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Fosfomycin-Trometamol 3000 mg (3 g every 24 h) for 10 days
Number of subjects: 240
Study 30518334 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg every 12 h for 10 days (standard of care)
Number of subjects: 240
Study 30518334 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Fosfomycin-Trometamol
Number of subjects: 240
Study 30518334 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 240
Study 27413136 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h urine collection (initial sample)
Number of subjects: 476
Study 27413136 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h urine collection (second sample)
Number of subjects: 476
Study 27413136 — intervention group
Group type: COMPARATOR
Intervention: Overall response rate for NHANES examination
Number of subjects: 476
Study 23294470 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM with tibial BMA (N = 6)
Number of subjects: 13
Study 23294470 — intervention group
Group type: COMPARATOR
Intervention: DBBM without tibial BMA (N = 6)
Number of subjects: 13
Study 23294470 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM with iliac BMAC (N = 7)
Number of subjects: 13
Study 23294470 — intervention group
Group type: COMPARATOR
Intervention: DBBM without iliac BMAC (N = 7)
Number of subjects: 13
Study 23242297 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal intervention (subgingival scaling and planing ultrasonic and manual)
Number of subjects: 57
Study 23242297 — intervention group
Group type: COMPARATOR
Intervention: Control group (supragingival prophylaxis)
Number of subjects: 57
Study 23242297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 57
Study 20697090 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (F)
Number of subjects: 375
Study 20697090 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine + cyclophosphamide (FC)
Number of subjects: 375
Study 20697090 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 mutation
Number of subjects: 375
Study 20697090 — intervention group
Group type: COMPARATOR
Intervention: FC treatment arm
Number of subjects: 375
Study 18299900 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 53
Study 18299900 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 53
Study 18299900 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 16841663 — intervention group
Group type: EXPERIMENTAL
Intervention: Three ways method of acupuncture
Number of subjects: 60
Study 16841663 — intervention group
Group type: COMPARATOR
Intervention: Hand and foot acupuncture
Number of subjects: 60
Study 12372571 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 298
Study 12372571 — intervention group
Group type: COMPARATOR
Intervention: PTCR
Number of subjects: 298
Study 10459590 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Compression-Decompression (ACD) CPR
Number of subjects: 90
Study 10459590 — intervention group
Group type: COMPARATOR
Intervention: Standard (STD) CPR
Number of subjects: 90
Study 7485874 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 18
Study 7485874 — intervention group
Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 18
Study 2272259 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone (R)
Number of subjects: 5
Study 2272259 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia alone (H)
Number of subjects: 5
Study 2272259 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hyperthermia and radiation (RH)
Number of subjects: 5
Study 2272259 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hyperthermia and radiation (HR)
Number of subjects: 5
Study 6936555 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable diameter dental floss
Number of subjects: 15
Study 6936555 — intervention group
Group type: COMPARATOR
Intervention: Conventional unwaxed dental floss
Number of subjects: 15
Study 30548170 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid peel
Number of subjects: 30
Study 30548170 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling with dermapen
Number of subjects: 30
Study 30548170 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glycolic acid peel and microneedling
Number of subjects: 30
Study 28699041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Rate Variability (PRV) analysis
Number of subjects: 51
Study 28699041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Transit Time (PTT) analysis
Number of subjects: 51
Study 25646170 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL
Number of subjects: 30
Study 25646170 — intervention group
Group type: COMPARATOR
Intervention: SRP with application of 810 nm diode laser
Number of subjects: 30
Study 25646170 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 30
Study 23824419 — intervention group
Group type: EXPERIMENTAL
Intervention: GH administration
Number of subjects: 62
Study 23824419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 22106300 — intervention group
Group type: EXPERIMENTAL
Intervention: Equitable decision making
Number of subjects: 0
Study 22106300 — intervention group
Group type: EXPERIMENTAL
Intervention: Inequitable decision making
Number of subjects: 0
Study 19284928 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/Fluoxetine Combination (OFC)
Number of subjects: 1146
Study 19284928 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 1146
Study 19284928 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 1146
Study 17442584 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GP)
Number of subjects: 40
Study 17442584 — intervention group
Group type: COMPARATOR
Intervention: Naproxen Sodium (NS)
Number of subjects: 40
Study 15715103 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy in conjunction with roentgeno‐endovascular occlusion of the internal ileal arteries and/or regional chemotherapy
Number of subjects: 308
Study 15715103 — intervention group
Group type: COMPARATOR
Intervention: Standard combined therapy
Number of subjects: 308
Study 11441134 — intervention group
Group type: EXPERIMENTAL
Intervention: G-to-T transversion at the first nucleotide of exon 5 causing G154V missense mutation
Number of subjects: 1
Study 11441134 — intervention group
Group type: EXPERIMENTAL
Intervention: T-to-C transition in the invariant GT at position +2 of the 5' donor splice site of intron 8
Number of subjects: 1
Study 9471039 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-adjusted prostate-specific antigen (PSAT)
Number of subjects: 61
Study 9471039 — intervention group
Group type: EXPERIMENTAL
Intervention: Total prostate volume PSA (PSA)
Number of subjects: 61
Study 9471039 — intervention group
Group type: EXPERIMENTAL
Intervention: Total prostate volume PSA density (PSAD)
Number of subjects: 61
Study 8543959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 500 mg twice daily
Number of subjects: 88
Study 8543959 — intervention group
Group type: COMPARATOR
Intervention: Control group received 10 mg of ascorbic acid twice daily
Number of subjects: 88
Study 2164194 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C/Ifosfamide
Number of subjects: 0
Study 2164194 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C/Vindesine
Number of subjects: 0
Study 2164194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/Etoposide
Number of subjects: 0
Study 2164194 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 373099 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 15
Study 373099 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide (thiazide diuretic)
Number of subjects: 15
Study 373099 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and Bendrofluazide combined
Number of subjects: 15
Study 373099 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide
Number of subjects: 15
Study 31149704 — intervention group
Group type: EXPERIMENTAL
Intervention: CrAg screening plus 4-weekly home visits for adherence support
Number of subjects: 1999
Study 31149704 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic-based care
Number of subjects: 1999
Study 31149704 — intervention group
Group type: EXPERIMENTAL
Intervention: CrAg screening plus adherence support
Number of subjects: 1999
Study 27744438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal probiotics with antibiotic prophylaxis
Number of subjects: 106
Study 27744438 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics only
Number of subjects: 106
Study 26152495 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate post-test (IPT)
Number of subjects: 115